GlassScriptPhysician profile
Mallory Deel
NPI 1790382463
$2,741.65
in general payments reported to CMS, 2019-2025
25 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,159 · 2022: $680 · 2023: $226 · 2024: $259 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.70 | 2021-2025 | |
| Alkermes, INC. | $229.69 | 2021-2025 | Vivitrol |
| Novo Nordisk INC | $179.35 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.71 | 2021-2022 | |
| Uswm, LLC | $143.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $130.93 | 2021-2022 | |
| Gilead Sciences, INC. | $124.74 | 2023 | Vemlidy |
| Viiv Healthcare Company | $124.74 | 2025 | Apretude |
| Otsuka America Pharmaceutical, INC. | $120.80 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Lilly USA, LLC | $110.65 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $95.03 | 2021 | |
| Pfizer INC. | $86.21 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $74.02 | 2021-2022 | |
| Glaxosmithkline, LLC. | $73.93 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $72.68 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.02 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $42.54 | 2021-2022 | |
| Amgen INC. | $38.66 | 2021 | |
| Dexcom, INC. | $32.10 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $26.26 | 2022 | |
| Lundbeck LLC | $18.11 | 2022 | |
| Biodelivery Sciences International, INC. | $17.66 | 2021 | |
| Eisai INC. | $17.20 | 2021 | |
| Indivior INC. | $11.87 | 2022 | |
| Adlon Therapeutics L.P. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Deel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.